Algorithms of using valproic acid drugs in women

Власов, П. Н.

doi:10.17116/jnevro20151154136-40

Z. nevrol. psikhiatr. im. S.S. Korsakova

2015

DOI: 10.17116/jnevro20151154136-40

|View full text |Cite

Algorithms of using valproic acid drugs in women

П. Н. Власов¹

Abstract: ЛЕЧЕНИЕ НЕРВНЫХ И ПСИХИЧЕСКИХ ЗАБОЛЕВАНИЙВ последние годы наблюдается существенный про-гресс в решении проблемы женского здоровья, в частно-сти ведения беременности у больных эпилепсией. Прово-дятся проспективные исследования по отдаленному влия-нию противоэпилептических препаратов (ПЭП) на физи-ческое и психическое развитие ребенка, изучается риск развития нервной и психической патологии у детей, воз-никающей при приеме матерью во время беременности ПЭП. Накоплен значительный объем данных, потребо-вавший пере… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2023

Publication Types

Select...

Article5

Relationship

Self Cite1

Independent4

Authors

Journals

Cited by 6 publications

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Withdrawal of valproic acid during pregnancy in women with epilepsy

Navumava¹,

Власов

Prusakova

et al. 2023

RJTAO

Self Cite

View full text Add to dashboard Cite

Objective: to analyze the course of epilepsy in women after withdrawal of valproic acid (VA) during pregnancy. Material and methods. The study was conducted in the Center of paroxysmal conditions of Vitebsk Regional Clinical Diagnostic Center. The study included 58 women with epilepsy who gave birth in 2018–2020; a prospective analysis was also done using the Russian Register of Pregnancy and Epilepsy (RRPE) data. The study group included 112 women with epilepsy who were taking VA at the time of conception. In 16.1% of cases (n=18 out of 112) VA was discontinued in the first trimester (withdrawal group), in 83.9% of cases (n=94) VA therapy was continued. We analyzed the frequency of epileptic seizures depending on the use of VA during pregnancy for each trimester and for the entire pregnancy as a whole. Results. According to the Vitebsk Regional Clinical Diagnostic Center, 32 out of 58 (55.2%) patients took VA, all of them had generalized tonicclonic seizures in the structure of epileptic seizures. Seven of 32 patients (21.8%) received VA at a dose of <700 mg/day; 10 (31.3%) – 700–1000 mg/day, 15 (46.9%) – 1000–1500 mg/day. VA was canceled in two cases, in one of them a tonic-clonic seizure developed. According to the RRPE data, in 9 out of 65 (13.8%) cases VA was discontinued in the first trimester (withdrawal group), in 55 out of 65 (84.6%) cases the therapy with VA was continued, and in one case - the drug was changed. The number of women with epilepsy taking VA during pregnancy has decreased from 38.9% (275 out of 707) in 2017 to 24.9% (112 out of 450) by January 2023. According to the RRPE, the majority of patients continued VA therapy during gestation if pregnancy occurred while taking this antiepileptic drug. A high fraction of prescribing VA in patients with focal epilepsy was registered – 58.9% (66 out of 112) with continuation of VA therapy during pregnancy in 61.7% of cases. Among patients with generalized form of epilepsy, VA drugs were taken by 36.6% (41 out of 112). The majority of patients (35.1%; 33 of 94) continued to take VA throughout the entire gestation. About half of the patients took VA at a dose of >700 mg/day in the first trimester and throughout gestation. There were no statistically significant differences in the frequency of tonic-clonic and other types of epileptic seizures during pregnancy in patients who canceled VA and continued therapy, according to RRPE. Conclusion. Further prospective and controlled studies with large sample sizes are needed to determine the most effective and safe strategy for VA withdrawal.

show abstract

Withdrawal of valproic acid during pregnancy in women with epilepsy

Navumava¹,

Власов

Prusakova

et al. 2023

RJTAO

Self Cite

View full text Add to dashboard Cite

show abstract

Compression anastomoses with nikelid-titanium rings in peritonitis

Дибиров

Isaev

Фомин

2018

Khir. Z. im. N.I. Pirogova

View full text Add to dashboard Cite

show abstract

A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis

et al. 2016

Z. nevrol. psikhiatr. im. S.S. Korsakova

View full text Add to dashboard Cite

Twenty-five percent of patients treated with cinnoVex were withdrawn from the study due to the non-efficacy (mean frequency of relapses was the same before and after treatment). A significant decrease of relapses was noted in patients treated with genfaxon. The high frequency of side-effects was the major problem in the treatment withgenfaxon. Due to this reason, some patients stopped treatment.A significant decrease of relapses was noted in patients treated with rebif though aversive effects were frequent during the first year of treatment. The effects of biosimilars found in this study are in line with earlier reports. Therefore, the increase of the quality of interferon-beta-1a biosimilars used for MS treatment is needed.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Algorithms of using valproic acid drugs in women

Cited by 6 publications

References 19 publications

Withdrawal of valproic acid during pregnancy in women with epilepsy

Withdrawal of valproic acid during pregnancy in women with epilepsy

Compression anastomoses with nikelid-titanium rings in peritonitis

A comparison analysis of the use of intravenous β-interferon-1a 30 mcg and subcutaneous β-interferon-1a 44 mcg in routine clinical practice of treatment in patients with multiple sclerosis

Contact Info

Product

Resources

About